Definitive Contract 75D30124C18579

Award Date 4/1/24
Potential Completion Date 3/31/28
Potential Value $233K
Federal Agency
CDC Pittsburgh
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Atlanta, GA 30329, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services Centers for Disease Control and Prevention (CDC) awarded a firm fixed price purchase order contract to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The $22,376.85 contract is for the provision of an ISEQ 100 SYSTEM, with a completion date of March 1, 2026. This award does not have a set-aside designation. Illumina has previously received prime federal contracts from agencies such as the NIH,...
The Department of Health and Human Services Centers for Disease Control and Prevention (CDC) awarded a firm fixed price purchase order to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis, for ILLUMINA ISEQ 100 I1 REAGENT. The potential value of this contract is $9,991.97. This award is not associated with any larger contract vehicle and does not have a set-aside designation. Illumina has previously provided sequencing systems, reagents,...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a firm fixed price purchase order to Illumina, Inc., a manufacturer of sequencing and array-based solutions, for preventative maintenance services on MISEQ and NOVASEQ sequencing instruments. The contract has a potential value of $125,869.80 and a completion date of November 19, 2022. Illumina has previously provided a range of sequencing systems, reagents, and services to support genomic research...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $54,367.08 firm fixed price purchase order to Illumina, Inc., a for-profit manufacturer of sequencing and genomic analysis instruments and reagents. The contract is for the repair/replacement and advanced support plan for ISEQ equipment, with performance to be completed by August 20, 2028. Illumina has previously provided sequencing systems, consumables, and services to support genomic research and...
This is a firm fixed price purchase order awarded by the Centers for Disease Control and Prevention (CDC) to Illumina, Inc., a for-profit manufacturer of genetic sequencing instruments and reagents. The contract is for the provision of an Illumina MiSeq genomic sequencing system, with a ceiling value of $135,435.37 and a performance period ending on November 30, 2015. The order does not have a set-aside designation. Illumina has previously received prime federal contract awards from agencies...
This is a firm fixed price purchase order awarded by the Centers for Disease Control and Prevention (CDC) to Illumina, Inc., a for-profit manufacturer of genetic and genomic analysis instruments and reagents. The $142,452.50 contract is for the provision of an MISEQDX lab instrument and care plan. The award does not have a set-aside designation. Illumina is a well-established provider of genomic sequencing systems and supplies to various federal agencies, including the National Institutes of...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a 5-year, Firm Fixed Price purchase order valued at $211,080.73 to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The award is for maintenance services to support Illumina's sequencing platforms, such as NextSeq, NovaSeq, MiSeq, and iSeq, which are used across federal agencies including the NIH, CDC, USDA, and VA for research and diagnostics...
This federal contract award to Illumina, Inc. is for the procurement of a MiSeq System, a genetic sequencing platform and associated consumables and services. The $93,529 firm fixed price contract was awarded by the Centers for Disease Control and Prevention (CDC) Pittsburgh. The contract does not have a set-aside designation. Illumina is a leading manufacturer of advanced genetic sequencing instruments, reagents, and bioinformatics software. The company has been awarded multiple federal...
The Department of Health and Human Services Centers for Disease Control and Prevention (CDC) awarded a $241,046.40 firm fixed-price purchase order to Illumina, Inc. to provide reagents and supplies. The award has no set-aside designation. Illumina is a manufacturer and provider of genetic sequencing instruments and analytical products. This award aligns with Illumina's past prime federal contracts to support genomic sequencing and analysis for various government agencies including the CDC,...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a firm-fixed-price Blanket Purchase Agreement (BPA) call to Illumina, Inc., a manufacturer of genetic sequencing systems and reagents, to provide six "Illumina MiSeq Kit v2 (500 Cycle) - 20 Pack" for $132,114.00. This contract does not have a set-aside designation. Illumina has previously provided sequencing instruments, reagents, and related services to federal agencies such as the NIH,...

The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $233,447.32 firm fixed price contract to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The contract, which has no set-aside designation, is for MISEQ SUPPORT SERVICES with a period of performance ending on March 31, 2028. Illumina, which has a history of providing sequencing systems, reagents, and related services to federal agencies, will deliver these support services from its facility in Atlanta, Georgia. While the original solicitation was not provided, the award indicates the CDC has an ongoing need for Illumina's genomic sequencing capabilities to support its research and diagnostic programs.

Generated 4/2/24, 3:00 PM